Back to Search Start Over

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

Authors :
Doriana Landi
Marco Iannetta
Mirko Compagno
Pietro Vitale
Novella Cesta
Christof Stingone
Vincenzo Malagnino
Girolama Alessandra Marfia
Elisabetta Teti
Ilaria Spalliera
Andrea Di Lorenzo
Loredana Sarmati
Giuseppe De Simone
Benedetta Rossi
Lorenzo Ansaldo
Massimo Andreoni
Carolina Gabri Nicoletti
Source :
Multiple Sclerosis and Related Disorders
Publication Year :
2020
Publisher :
Elsevier B.V., 2020.

Abstract

Highlights • Ocrelizumab is not associated to increased severity in MS patients with COVID-19. • B-cell depleting treatment could impact on virus-specific antibody production. • B-cell depleting therapies can reduce IL-6 production, thus modulating inflammation.<br />Background Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS). Objectives to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment. Methods Case series. Results Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae. Conclusion Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.

Details

Language :
English
ISSN :
22110356 and 22110348
Volume :
45
Database :
OpenAIRE
Journal :
Multiple Sclerosis and Related Disorders
Accession number :
edsair.doi.dedup.....152e0915d1272ea5d822451c0aaaa738